Endogenous signalling nucleoside acting at four GPCR subtypes: A1 (cardiac slowing, inhibition of NE release), A2A (vasodilation, wakefulness suppression — caffeine's principal target), A2B, A3. Accumulates with neural activity and is the presumed somnogen driving sleep pressure. Extremely short plasma t½ (seconds) — deaminated to inosine by adenosine deaminase.
Half-Life & Elimination Curve (IV: 0m)
Elimination (IV)
0×t½0h100%(0.286 mg/L)
1×t½0m50%(0.143 mg/L)
2×t½0m25%(71.4 µg/L)
3×t½1m12.5%(35.7 µg/L)
4×t½1m6.3%(17.9 µg/L)
5×t½1m3.1%(8.93 µg/L)
Elimination t½0m (IV)
Rate Constant (ke)248 h⁻¹
Est. Peak (Cmax)0.286 mg/L
Clearance (CL)5200 L/h
97% Washout (5×t½)1m
Dosing Guidelines
Intravenous (IV): Typical 6 mg
Pharmacokinetic Parameters
Intravenous (IV): Volume of Distribution (Vd): 21 L [PMID 2184971]
Caffeine (caution): Caffeine is a non-selective A1/A2A antagonist — reduces endogenous adenosine effects and blunts IV adenosine's clinical potency (hold caffeine ≥24 h before stress testing).
Dipyridamole (major): Dipyridamole blocks ENT1-mediated cellular re-uptake of adenosine, raising extracellular levels severalfold and profoundly amplifying SA/AV-node slowing, vasodilation, and risk of bronchospasm from exogenous IV adenosine — reduce IV adenosine dose or choose an alternate stress agent. [Meester 1998]
PEAK ATP (synergistic): Adenosine is the terminal dephosphorylation product — extracellular signalling convergence.